Is Eton Pharmaceuticals, Inc. (ETON) a Buy, Sell, or Hold?
NASDAQ : ETON
Eton Pharmaceuticals, Inc.
$37.19 USD
-$1.31 (-3.4%)
- Volume
- 441.11K
- Average Volume
- 412.5K
- Market Capitalization
- $1.02B
- P/E Ratio
- -727.79
- Dividend Yield
- 0.00%
- Price Target
- $58.50
- Year High
- $39.48
- Year Low
- $13.78
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.21
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Sean E. Brynjelsen |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Current Symbol | ETON |
| CUSIP | 29772L108 |
| CIK | 0001710340 |
| Web | https://www.etonpharma.com |
| Phone | 847 787 7361 |
| Currency | USD |
| Employees | 44 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.40 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.21 |
| Quick Ratio | 0.88 |
| Cash Ratio | 0.45 |
Sales & Book Value
| Annual Sales | $79.95M |
| Price / Sales | 11.72 |
| Cash Flow | 0.57 |
| Price / Cash Flow | 66.02 |
| Price / Book | 33.14 |
Price Target and Rating
| Average Stock Price Forecast | $58.50 |
| High Stock Price Forecast | $60.00 |
| Low Stock Price Forecast | $57.00 |
| Forecast Upside/Downside | -36.43% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 6 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$0.17 |
| Trailing P/E Ratio | -727.79 |
| PEG Ratio | 57.02 |
| P/E Growth | 57.02 |
| Net Income | -$4.6M |
| Net Margin | -1.70% |
| Pretax Margin | -1.71% |
| Return on Equity | -5.68% |
| Return on Assets | -1.51% |
Financials Score
| AltmanZ Score | 8.89 |
| Piotroski Score | 4.00 |
| Working Capital | 9.07M |
| Total Assets | 97.71M |
| Ebit | 1.29M |
| Market Cap | 1.05B |
| Total Liabilities | 67.1M |
Poll Results
About Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adre ... nal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Eton Pharmaceuticals Inc (ETON) Shares Fall 4.3% -- What GF Score of 70 Tells Investors
2026-05-29 20:22:00
On May 29, 2026, Eton Pharmaceuticals Inc (ETON) shares fell 4.3% today, bringing the current price to $30.46. The stock has experienced significant volatility,
2026-05-19 16:30:00
DEER PARK, Ill., May 19, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced it has entered into a supply and distribution agreement for the United States commercialization rights to IMPAVIDO® (miltefosine) from an affiliate of Knight Therapeutics, Inc (“Knight”). IMPAVIDO® is an orphan drug indicated for the treatment of visceral, cutaneous, and mucosal leishmaniasis caused by specific Leishmania species in adults and adolescents over the age of 12 and weighing more than 30 kilograms. Please see indications and important safety information below.
Eton Pharmaceuticals, Inc. (ETON) Q1 2026 Earnings Call Transcript
2026-05-14 21:00:45
Eton Pharmaceuticals, Inc. (ETON) Q1 2026 Earnings Call Transcript
Eton Pharmaceuticals Q1 Earnings Call Highlights
2026-05-14 20:05:48
Eton Pharmaceuticals NASDAQ: ETON raised its 2026 revenue outlook after reporting record first-quarter product sales and highlighting early progress from two recent product launches, DESMODA and HEMANGEOL.
Eton Pharmaceuticals, Inc. (ETON) Misses Q1 Earnings Estimates
2026-05-14 18:31:06
Eton Pharmaceuticals, Inc. (ETON) came out with quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.07 per share a year ago.
Eton Pharmaceuticals Reports First Quarter 2026 Financial Results
2026-05-14 16:05:00
Q1 2026 product sales of $24.3 million, representing 73% growth over Q1 2025 Raising full year revenue guidance - now expect 2026 revenue to exceed $120 million, up from previous guidance of $110 million Q1 2026 fully diluted GAAP EPS of $0.05, non-GAAP fully diluted EPS of $0.14, and Adjusted EBITDA of $5.7 million Received FDA approval for and launched DESMODA™ Acquired and relaunched HEMANGEOL® Announced initiation of ET-700 clinical study, the Company's extended-release formulation of zinc acetate Received FDA clearance to proceed on INCRELEX® label harmonization study Management to hold conference call today at 4:30pm ET DEER PARK, Ill., May 14, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended March 31, 2026.
Eton Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-05-12 16:30:00
DEER PARK, Ill., May 12, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that executive management will participate in three upcoming investor conferences as follows:
Eton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
2026-05-04 16:30:00
DEER PARK, Ill., May 04, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2026 financial results on Thursday, May 14, 2026.
Frequently Asked Questions
-
What is the current Eton Pharmaceuticals, Inc. (ETON) stock price?
-
Eton Pharmaceuticals, Inc.(NASDAQ:ETON) stock price is $37.19 in the last trading session. During the trading session, ETON stock reached the peak price of $39.4799 while $13.78 was the lowest point it dropped to. The percentage change in ETON stock occurred in the recent session was --3.4% while the dollar amount for the price change in ETON stock was -$1.31.
-
ETON's industry and sector of operation?
-
The NASDAQ listed ETON is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
-
Who are the executives of ETON?
-
David Krempa | Chief Business Officer
Danka Radosavljevic | Executive Vice President of Operations
James R. Gruber | Consultant
Sean E. Brynjelsen | President, Chief Executive Officer & Director
Ipek Erdogan-Trinkaus | Chief Commercial Officer -
How many employees does ETON have?
-
Number of ETON employees currently stands at 44. ETON operates from 21925 W. Field Parkway, Deer Park, IL 60010-7278, US.
-
Link for ETON official website?
-
Official Website of ETON is: https://www.etonpharma.com
-
How do I contact ETON?
-
ETON could be contacted at phone #847 787 7361 and can also be accessed through its website. ETON operates from 21925 W. Field Parkway, Deer Park, IL 60010-7278, US.
-
How many shares of ETON are traded daily?
-
The average number of ETON shares traded daily for last 3 months was 412.5K.
-
What is the market cap of ETON currently?
-
The market value of ETON currently stands at $1.02B with its latest stock price at $37.19